Guobing Yin

Guobing Yin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YMYu Min
Yu Min
YHYizhou Huang
Yizhou Huang
MWMinjie Wei
Minjie Wei
XWXiaoyuan Wei
Xiaoyuan Wei
HCHang Chen
Hang Chen
GYGuobing Yin
Guobing Yin
Background: The preoperative distinguishment of lymph nodes with reactive hyperplasia or tumor metastasis plays a pivotal role in guiding the surgical extension for papillary thyroid carcinoma (PTC) with Hashimoto’s thyroiditis (HT), especially in terms of the central lymph node (CLN) dissection. We aim to identify the preparative risk factors for CLN metastasis in PTC patients concurrent with HT.Materials and Methods: We retrospectively reviewed and analyzed the data including the basic information, preoperative sonographic characteristics, and thyroid function of consecutive PTC patients with HT in our medical center between Jan 2019 and Apr 2021. The Chi-square and Fisher’s exact tests were used for comparison of qualitative variables among patients with or without CLN metastasis. Univariate and multivariate logistic regression analyses were used to determine the risk factors for CLN metastasis. The nomogram was constructed and further evaluated by two cohorts produced by 1,000 resampling bootstrap analysis.Results: A total of 98 in 214 (45.8%) PTC patients were identified with CLN metastasis. In multivariate analysis, four variables including high serum thyroglobulin antibody (TgAb) level (>1,150 IU/ml), lower tumor location, irregular margin of CLN, and micro-calcification in the CLN were determined to be significantly associated with the CLN metastasis in PTC patients with HT. An individualized nomogram was consequently established with a favorable C-index of 0.815 and verified via two internal validation cohorts.Conclusions: Our results indicated that preoperatively sonographic characteristics of the tumor and lymph node condition combined with serum TgAb level can significantly predict the CLN in PTC patients with HT and the novel nomogram may further help surgeons to manage the CLN in this subpopulation.

14 February 2021 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
YFY. Feng
Y. Feng
YMY. Min
Y. Min
HCH. Chen
H. Chen
KXK. Xiang
K. Xiang
XWX. Wang
X. Wang
GYGuobing Yin
Guobing Yin

1 December 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YMYu Min
Yu Min
XWXing Wang
Xing Wang
HCHang Chen
Hang Chen
JCJialin Chen
Jialin Chen
KXKe Xiang
Ke Xiang
GYGuobing Yin
Guobing Yin
Purpose: Thermal ablation (TA), as one of the most currently remarkable technologies, has achieved great success in many malignant diseases including but not limited to hepatic and renal carcinoma. In recent years, this technology was gradually introduced to the treatment of papillary thyroid microcarcinoma (PTMC) and even papillary thyroid carcinoma (PTC). Thereby, we summarized the current progress of TA development in the treatment of PTMC. Methods: The latest relevant literature from the PubMed database with keywords “thermal ablation”, “papillary thyroid microcarcinoma”, “microwave ablation”, “radio-frequency ablation”, and “laser ablation”, among others, were comprehensively reviewed in this article. The follow-up outcomes of patients in these articles were analyzed. Results: The efficacy and safety of TA including microwave ablation (MWA), laser ablation (LA), and radiofrequency ablation (RFA) in the treatment of PTC and PTC have been intensively studied. Based on existing clinical trials, the relatively long-term follow-up (range, from 6 to 64.2 months) results in MWA, LA, and RFA were satisfactory that tumor volume reduction rate (VRR) reached and even surpass 99%. Compared with routine surgery methods (total thyroidectomy and lobectomy), the incidence rate of complications was relatively lower and the recurrence rate of TA techniques was not statistically significant, whereas the operative time, blood loss, length of hospital stay, and hospital cost were significantly decreased. Conclusion: TA presents the same satisfactory therapeutic effects but minimal postoperative trauma can significantly improve the patients’ quality of life. However, future larger sample, multicenter, and prospective randomized controlled trials are urgently needed to validate the feasibility of TA in dealing with PTMC.

6 August 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XWXing Wang
Xing Wang
GYGuobing Yin
Guobing Yin
WZWei Zhang
Wei Zhang
KSKunling Song
Kunling Song
LZLongbin Zhang
Longbin Zhang
ZGZufeng Guo
Zufeng Guo
Altered tumor metabolism is a hallmark of cancer and targeting tumor metabolism has been considered as an attractive strategy for cancer therapy. Prostaglandin Reductase 1 (PTGR1) is a rate-limiting enzyme involved in the arachidonic acid metabolism pathway and mainly responsible for the deactivation of some eicosanoids, including prostaglandins and leukotriene B4. A growing evidence suggested that PTGR1 plays a significant role in cancer and has emerged as a novel target for cancer therapeutics. In this review, we summarize the progress made in recent years toward the understanding of PTGR1 function and structure, highlight the roles of PTGR1 in cancer, and describe potential inhibitors of PTGR1. Finally, we provide some thoughts on future directions that might facilitate the PTGR1 research and therapeutics development.

7 September 2021 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
XWX. Wei
X. Wei
YMY. Min
Y. Min
YFY. Feng
Y. Feng
DHD. He
D. He
XZX. Zeng
X. Zeng
DHD. Hu
D. Hu

1 January 2020 in International Journal of Medical Sciences
Verified
Journal Article
Open access
YMYu Min
Yu Min
XWXing Wang
Xing Wang
HCHang Chen
Hang Chen
GYGuobing Yin
Guobing Yin
Hashimoto's thyroiditis (HT) is the most prevalent autoimmune thyroid disease (ATD) worldwide and is strongly associated with miscarriage and even recurrent miscarriage (RM). Moreover, with a deepening understanding, emerging evidence has shown that immune dysfunctions caused by HT conditions, including imbalanced subsets of CD4+ T-helper cells, B regulatory (Breg) cells, high expression levels of CD56dim natural killer (NK) cells, and cytokines, possibly play an important role in impairing maternal tolerance to the fetus. In recent years, unprecedented progress has been made in recognizing the specific changes in immune cells and molecules in patients with HT, which will be helpful in exploring the mechanism of HT-related miscarriage. Based on these findings, research investigating some potentially more effective treatments, such as selenium (Se), vitamin D3, and intravenous immunoglobulin (IVIG), has been well developed over the past few years. In this review, we highlight some of the latest advances in the possible immunological pathogenesis of HT-related miscarriage and focus on the efficacies of treatments that have been widely introduced to clinical trials or practice described in the most recent literature.